Organon & Co banner

Organon & Co
XBER:7XP

Watchlist Manager
Organon & Co Logo
Organon & Co
XBER:7XP
Watchlist
Price: 6.048 EUR Market Closed
Market Cap: €1.6B

Relative Value

The Relative Value of one 7XP stock under the Base Case scenario is hidden EUR. Compared to the current market price of 6.048 EUR, Organon & Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

7XP Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

7XP Competitors Multiples
Organon & Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Organon & Co
XBER:7XP
1.7B EUR 0.3 9.1 5.7 7.2
US
Eli Lilly and Co
NYSE:LLY
952.7B USD 14.6 46.2 31.1 33.2
US
Johnson & Johnson
NYSE:JNJ
584.1B USD 6.2 21.8 15.1 18.6
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 20.5 12.1 13.6
CH
Novartis AG
SIX:NOVN
238.2B CHF 5.3 21.5 13.3 17.1
UK
AstraZeneca PLC
LSE:AZN
223.5B GBP 5.1 29.4 16.3 22.9
US
Merck & Co Inc
NYSE:MRK
289.8B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.7 11.1 8.2 9.6
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.4 19.6 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2.5 17.3 7.3 9
P/E Multiple
Earnings Growth PEG
US
Organon & Co
XBER:7XP
Average P/E: 21.2
9.1
80%
0.1
US
Eli Lilly and Co
NYSE:LLY
46.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
20.5
14%
1.5
CH
Novartis AG
SIX:NOVN
21.5
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.4
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Organon & Co
XBER:7XP
Average EV/EBITDA: 42.9
5.7
7%
0.8
US
Eli Lilly and Co
NYSE:LLY
31.1
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
12.1
6%
2
CH
Novartis AG
SIX:NOVN
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.3
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.2
1%
8.2
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Organon & Co
XBER:7XP
Average EV/EBIT: 92.6
7.2
11%
0.7
US
Eli Lilly and Co
NYSE:LLY
33.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.6
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
CH
Novartis AG
SIX:NOVN
17.1
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett